Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 7/20 | 0.41 |
| ▸ | KIT | P10721 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 4/20 | 0.31 |
| ▸ | PPARA | Q07869 | 4/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9924140 | 0.91 | ALOX5AP (0.53) | ALOX5APKITMAPTPPARDPPARA | |
| SCHEMBL9924141 | 0.87 | ALOX5AP (0.36) | ALOX5APHSD11B1 | |
| SCHEMBL480001 | 0.86 | ALOX5AP (0.57) | ALOX5APKITMAPT | |
| SCHEMBL9924139 | 0.84 | ALOX5AP (0.43) | ALOX5APMAPTTSHRS1PR1PPARD | |
| SCHEMBL480298 | 0.82 | ALOX5AP (0.39) | ALOX5APMAPTNPC1CASP3RAB9A | |
| SCHEMBL2991804 | 0.82 | ALOX5AP (0.47) | ALOX5APMAPTS1PR1PPARDPPARA | |
| SCHEMBL3000722 | 0.78 | ACACB (0.35) | ALOX5APMAPTS1PR1PPARDPPARA | |
| SCHEMBL480173 | 0.76 | ALOX5AP (0.55) | ALOX5APKITMAPTNPC1RAB9A | |
| SCHEMBL14396685 | 0.75 | ALOX5AP (0.48) | ALOX5APNPC1RAB9A | |
| SCHEMBL709386 | 0.75 | ALOX5AP (0.56) | ALOX5APAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426413-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| US-8426413-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20120149674-A1 | Diaryl Substituted Alkanes | MERCK SHARPE & DOHME CORP. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149674-A1 | Diaryl Substituted Alkanes | MERCK SHARPE & DOHME CORP. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8124628-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124628-B2 | Diaryl substituted alkanes | MERCK SHARP & DOHME CORP. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2009-10-15 | — | — | US | disclosed |
| WO-2007120574-A2 | DIARYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149674-A1 | Diaryl Substituted Alkanes | ALOX5, ALOX15, LTB4R2 | ALOX5AP 13/4885KIT 540/4885MAPT 4815/4885 |
| US-20090258851-A1 | DIARYL SUBSTITUTED ALKANES | ALOX5, ALOX15, LTB4R2 | ALOX5AP 13/4885KIT 540/4885MAPT 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.